Serum Thymidine Kinase 1 - Potential Prostate Cancer Biomarker: A Clinical Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F23%3A10458482" target="_blank" >RIV/00064165:_____/23:10458482 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10458482 RIV/00216208:11110/23:10458482 RIV/00064203:_____/23:10458482
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=grVrYcceOw" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=grVrYcceOw</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.16319" target="_blank" >10.21873/anticanres.16319</a>
Alternative languages
Result language
angličtina
Original language name
Serum Thymidine Kinase 1 - Potential Prostate Cancer Biomarker: A Clinical Study
Original language description
BACKGROUND/AIM: Serum thymidine kinase 1 (STK1) is a proliferation biomarker that has been used as a diagnostic marker of several malignant diseases. However, there are limited data for prostate cancer (PCa). PATIENTS AND METHODS: In this study, we retrospectively analysed serum samples from 169 patients with biopsy confirmed PCa, who had been indicated for radical prostatectomy (RP) between 2013-2016. The results were compared with those in serum samples from 39 healthy men. We used commercially available enzymatic immunoassay to determine the levels of STK1. The patients were divided into groups according to the Gleason score (GS) and risk factors for adjuvant radiotherapy (aRT), which were defined as GS 8-10, pT3, and a positive surgical margin. RESULTS: The median serum level of STK1 in PCa patients was 0.289 pmol/l. In the control group, the median value was 0.0116 pmol/l (p<0.001). By comparing the patients with GS<=6 vs. 7 vs. >=8 (p=0.01), we found statistically significant differences. In the correlation of STK1 values with risk factors, we found statistically significant differences both in comparison of 0 vs. 1 vs. 2 vs. 3 risk factors (p=0.021), as well as <=1 vs. 2>= risk factors (p=0.009). CONCLUSION: The levels of STK1 are significantly higher in patients with PCa than those in healthy controls. Furthermore, STK1 values correlate with GS and predefined risk factors for aRT. Therefore, STK1 can be considered as a potential tumour marker of PCa diagnosis and risk stratification.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer Research
ISSN
0250-7005
e-ISSN
1791-7530
Volume of the periodical
43
Issue of the periodical within the volume
4
Country of publishing house
GR - GREECE
Number of pages
6
Pages from-to
1675-1680
UT code for WoS article
000990845600002
EID of the result in the Scopus database
2-s2.0-85150943913